RPRX Articles, Royalty Pharma plc

During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks...

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it is scheduled to participate in a fireside c...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) announced today that it has priced an offering of $1.5 billion of s...

Tuesday, Agios Pharmaceuticals Inc (NASDAQ:AGIO) agreed to sell its rights to its 15% royalty on potential U.S. net sales ...

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clini...

On Wednesday, Royalty Pharma plc (NASDAQ:RPRX) and Cytokinetics Incorporated (NASDAQ:CYTK) entered into a strategic fundin...

Royalty Pharma (NASDAQ: RPRX) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.96 per share. This co...

Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 202...

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases...

Amgen Inc. (NASDAQ:AMGN) reported first-quarter financial results after the closing bell Thursday. Here's a look at the highlights. The Detai...